Promethera Biosciences has added to its Series C to support its expansion into major liver diseases including nonalcoholic steatohepatitis.

Small cap British biotech Adaptimmune will combine its experimental NY-ESO SPEAR T-cell therapy with Merck’s blockbuster checkpoint inhibitor Keytruda (…

The FDA has placed a partial clinical hold on a Phase III PD-L1 candidate from AstraZeneca due to bleeding adverse events in two clinical trials.

Investors plowed $116 million in a Series B round into Unity Biotechnology, which is focusing its early work on halting atherosclerotic disease.

Allergan is buying Motus Therapeutics, a subsidiary of Rhythm Holding designed to hold its diabetic gastroparesis treatment relamorelin, under an option deal…

ProQR Therapeutics saw its stock surge on the back of data from a small clinical trial of its cystic fibrosis drug QR-010.

DBV posts peanut allergy data, TiGenix looks to file for an IPO, Oasmia is buying a cancer drug and more.

In our EuroBiotech roundup this week, NeuroVive closes its Lyon subsidiary, ObsEva misses a primary endpoint, Active Biotech offloads a cancer drug, and more.

TiGenix has dusted off its plan to file for an IPO on Nasdaq and brought in a new set of underwriters.